|Description||NVP-BHG712 is a EphB4 kinase inhibitor and BCR-ABL inhibitor. NVP-BHG712, which inhibits EphB4 kinase activity in the low nanomolar range in cellular assays showed high selectivity for targeting the EphB4 kinase when profiled against other kinases in biochemical as well as in cell based assays. Furthermore, NVP-BHG712 shows excellent pharmacokinetic properties and potently inhibits EphB4 autophosphorylation in tissues after oral administration. In vivo, NVP-BHG712 inhibits VEGF driven vessel formation, while it has only little effects on VEGF receptor (VEGFR) activity in vitro or in cellular assays. The data shown here suggest a close cross talk between the VEGFR and EphR signaling during vessel formation. In addition to its established function in vascular remodeling and endothelial arterio-venous differentiation, EphB4 forward signaling appears to be an important mediator of VEGF induced angiogenesis since inhibition of EphB4 forward signaling is sufficient to inhibit VEGF induced angiogenesis.|
|Synonyms||NVP-BHG712; BHG712; BHG-712|
ALW-II-41-27 is an effective inhibitor of EPH family kinases that has been found to be related to lung cancers. IC50: 11 nM to EPHA2.
Rhynchophylline is a novel erythropoietin-producing hepatocellular A4 (EphA4) inhibitor. It is an alkaloid isolated from the herbs of Uncaria rhynchophylla. It ...
NVP-BHG712 is a EphB4 kinase inhibitor and BCR-ABL inhibitor. NVP-BHG712, which inhibits EphB4 kinase activity in the low nanomolar range in cellular assays s...
JI-101 is an orally active inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFRb), and the e...
HG-9-91-01，a small molecule inhibitor that targets specificly salt-inducible kinase (SIKs) IC50: SIK1=0.92 nM; SIK2=6.6 nM; SIK3=9.6 nM